PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12693427-3	2002	In all studies a significant improvement was observed on the Scale for the Assessment of Negative Symptoms (SANS) in the amisulpride groups (50-300 mg daily) as compared to placebo.	Amisulpride	121-132	USH1 protein network component sans	Homo sapiens	108-112	
9218164-6	1997	Mean total scores for the Scale for the Assessment of Negative Symptoms (SANS) at baseline in the different treatment groups varied from 98 to 74, and improved significantly in the amisulpride groups (mean change from 24 to 40 points) compared with the placebo groups.	Amisulpride	181-192	USH1 protein network component sans	Homo sapiens	73-77	
7894879-6	1995	RESULTS: Both amisulpride doses were significantly more effective than placebo on the primary evaluation criterion (SANS total score, MANOVA P < 0.02).	Amisulpride	14-25	USH1 protein network component sans	Homo sapiens	116-120	
24794879-9	2014	Percent SANS improvement at endpoint was greatest for the rapid-responders group, a finding that replicated stratifying by placebo and amisulpride treatment groups.	Amisulpride	135-146	USH1 protein network component sans	Homo sapiens	8-12	
25535442-8	2014	RESULTS: The mean SANS score in amisulpride and olanzapine group at day 0 and day 60 were 83.89 (+-12.67) and 21.00 (+-11.82) and 84.40 (+-13.22) and 26.75 (+-12.41), respectively.	Amisulpride	32-43	USH1 protein network component sans	Homo sapiens	18-22	
25535442-10	2014	The percentage improvement in SANS, SAPS, SCoRS interviewer, and SCoRS global in amisulpride group are 74.96%, 13.36%, 54.14%, and 42.00%, respectively.	Amisulpride	81-92	USH1 protein network component sans	Homo sapiens	30-34